Related Experiment Video

Updated: Jun 1, 2026

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well
08:01

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well

Published on: February 27, 2026

Evaluation of hypercoagulability in obese children with thrombin generation test and microparticle release: effect of

Zeynep Siklar1, Gönül Öçal, Merih Berberoğlu

  • 1Department of Pediatric Endocrinology, Ankara University School of Medicine, Ankara, Turkey. zeynepsklr@gmail.com

Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
|May 20, 2011
PubMed

Insights

Childhood obesity is linked to a hypercoagulable state, with increased thrombin generation and microparticle levels observed. This suggests obesity itself, not metabolic issues, drives these coagulation changes in children.

Area of Science:

  • Pediatric Endocrinology
  • Hematology
  • Metabolic Disorders

Background:

  • Obesity is linked to a hypercoagulable state.
  • Thrombin generation test (TGT) and microparticle levels are not extensively studied in obese children.
  • Understanding coagulation differences in pediatric obesity is crucial.

Purpose of the Study:

  • To investigate coagulation system differences between obese and normal-weight children.
  • To assess thrombin generation and microparticle levels in pediatric obesity.
  • To explore correlations between coagulation parameters, obesity, and metabolic factors.

Main Methods:

  • A study involving 120 obese and 38 healthy children.
  • Utilized Thrombin Generation Test (TGT) to assess coagulation.
  • Measured microparticle levels and correlated with Body Mass Index (BMI) Standard Deviation Score (SDS) and metabolic parameters.

Main Results:

  • Obese children exhibited increased thrombin generation and microparticle levels compared to controls.
  • Hyperinsulinism was not identified as a risk factor for hypercoagulability in this cohort.
  • Microparticle release time correlated significantly with BMI SDS, independent of metabolic syndrome.

Conclusions:

  • Childhood obesity is associated with a hypercoagulable state.
  • Increased microparticle release in obese children may be driven by adipokines, independent of metabolic derangements.
  • Coagulation alterations in pediatric obesity warrant further investigation.

More Related Videos

Determination of the Procoagulant Activity of Extracellular Vesicle (EV) Using EV-Activated Clotting Time (EV-ACT)04:56

Determination of the Procoagulant Activity of Extracellular Vesicle (EV) Using EV-Activated Clotting Time (EV-ACT)

Published on: August 4, 2023

Pulse-Wave Velocity, Flow-Mediated Dilation, and Carotid Intima-Media Thickness to Assess Cardiovascular Risk in Population with Metabolic Syndrome06:04

Pulse-Wave Velocity, Flow-Mediated Dilation, and Carotid Intima-Media Thickness to Assess Cardiovascular Risk in Population with Metabolic Syndrome

Published on: September 27, 2024

Related Concept Videos

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...